Dehydrocorydaline chloride

Dehydrocorydaline chloride is an alkaloid with anti-inflammatory and anti-cancer activity. Can improve the activation of p38 MAPK.Treatment of C2C12 myoblasts with 500 nM dehydrocorydrine increased the expression level of muscle-specific proteins (including MyoD, myogenin and myosin heavy chain). Treatment with dehydrocorydrine can increase p38 MAPK activation and the interaction between MyoD and E protein. In addition, the treatment of dehydrohydroxyproline can restore the defects of differentiation-induced p38 MAPK activation and differentiation of myoblasts in C2C12 myoblasts induced by the differentiated early growth receptor protein Cdo. Dehydrohydroxyproline significantly inhibits the proliferation of MCF-7 cells in a dose-dependent manner, which can be reversed by the caspase-8 inhibitor Z-IETD-FMK. Dehydrohydroxyproline increases DNA fragments without affecting ΔΨm. Western blot analysis showed that dehydrocorydrine increased dose-dependently Bax protein expression and decreased Bcl-2 protein expression. In addition, dehydrohydroxyproline induces caspase-7,-8 activation and PARP cleavage without affecting caspase-9. These results indicate that dehydrohydroxyproline inhibits the proliferation of MCF-7 cells by inducing apoptosis by regulating Bax/Bcl-2, activating caspase and cleaving PARP.Dehydrocobaltate (3.6, 6 or 10 mg/kg, intraperitoneal injection) showed a dose-dependent anti-nociceptive effect in the acetic acid-induced writhing test and significantly reduced formalin-induced mice Pain reaction. In the formalin test, dehydrocorydrine can reduce the expression of caspase 6 (CASP6), TNF-α, IL-1β and IL-6 proteins in the spinal cord. It was confirmed that dehydroyanhusine has an analgesic effect on mice.